The UK and US have announced a key trade agreement that will guarantee zero tariffs on UK drug shipments being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase expenditure on medicines through the NHS. This pledge guarantees that import taxes on these key exports will be held at nothing for a period of the next three years.
This deal is in response to previous threats to hike duties on branded drug imports, with figures mentioned as high as double the cost.
"This agreement between the United Kingdom bolsters the international landscape for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. drug exports," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's most significant goods shipped to the US, which is easily the primary buyer for leading companies like GSK and AstraZeneca.
Statistics show that in the year to the end of the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that span.
"This deal protects employment, boosts investment and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact includes several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, repayments exceeded 20%.
Recent Tensions
The deal comes amid a protracted tension between the sector and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that US customers were paying significantly more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial investments have been announced toward American operations.
One official stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
